

Design Synthesis Characterization Of Some Novel Chromane Based Analogues And Its Antimicrobial Evaluation

Anjali Gupta¹, Praveen Kumar Arora², V. Deepha³, Shelke Sujit Kisan⁴, Shubhankar Saha⁵, Muggu Murali Krishna⁶, Prem Shankar Gupta⁷, Wasim Akhtar⁸, Asish Bhaumik^{9*}

¹Galgotias College of Pharmacy, Knowledge Park II, Greater Noida 201310, Uttar Pradesh, India

²Associate Professor, Geeta Institute of Pharmacy, Geeta University, Naultha, Panipat, Haryana, 132145, India

³Assistant Professor, Bannari Amman Institute of Technology, Sathyamangalam- 638401, India

⁴Lecturer, D. P. Kharde Navjeevan College of Pharmacy. Nashik, Maharashtra, 422606, India

⁵Assistant Professor, Department of Pharmacology, Bharat Pharmaceutical Technology, Amtali, Agartala, Tripura, 799130, India

⁶Associate Professor, A.M Reddy Memorial College of Pharmacy Palnadu District, Andhra Pradesh, Narasaraopet, 522601, India

⁷Associate Professor, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, 244001, India

⁸Professor, DmbH Institute of Medical Science, Hooghly, West Bengal, 712305, India

⁹Associate Professor, Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Tezpur, Girijananda Chowdhury University, Tezpur Campus, Dekargaon, Tezpur, Assam-784501, India

***Corresponding Author: Asish Bhaumik**, Associate Professor, Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Tezpur, Girijananda Chowdhury University, Tezpur Campus, Dekargaon, Tezpur, Assam-784501, India

Abstract

Because of its diverse variety of pharmacological effects, chromane (4H-benzopyran) is a privileged scaffold in medicinal chemistry. In order to increase antibacterial activity, new chromane-based analogues were created and synthesized for this investigation. The produced compounds' antibacterial ability was assessed against a range of bacterial and fungal strains, and their structural characteristics were assessed through the use of spectroscopic techniques. Significant antibacterial activity was demonstrated by a number of compounds, suggesting that they could be excellent leads for more research. Numerous new compounds based on chromane were created and demonstrated encouraging antibacterial properties. Changes in structure have a major impact on potency. These results serve as a foundation for additional chromane analogue research and optimization as possible antibacterial agents.

Keyword: Chromane, Coumarin, antimicrobial, synthesis and characterization

INTRODUCTION

Public health is seriously threatened by the global increase in antimicrobial resistance (AMR), which makes the urgent search and development of novel treatment agents with enhanced efficacy and safety profiles necessary [1]. Because resistant bacteria strains are evolving so quickly, traditional antibiotics are losing their effectiveness. In order to meet this increasing challenge, medicinal chemistry has made the investigation of novel chemical scaffolds and molecular frameworks a primary priority [2, 3]. A unique class of heterocyclic compounds, chromane (4H-benzo[b]pyran) and its derivatives are recognized for a variety of biological actions, such as antibacterial, antioxidant, anti-inflammatory, anticancer, antidiabetic, and neuroprotective properties [4, 5]. The chromane scaffold's structural adaptability makes it a desirable template for the creation of new bioactive compounds because it permits a variety of chemical alterations [6]. The chromane core's biological significance is further shown by the fact that it is found in a number of naturally occurring flavonoids and tocopherols (derivatives of vitamin E) [7, 8].

Numerous research conducted over the past few decades have demonstrated the potential of compounds based on chromane as strong antibacterial agents [9]. The biological activity of these compounds has been demonstrated to be considerably impacted by strategic substitutions at several locations on the chromane ring, including C-2, C-3, C-6, and C-7 [10]. It has been very successful to enhance antibacterial characteristics by incorporating pharmacophores including sulfonamides, triazoles, amides, and heterocyclic moieties into the chromane framework [11, 12].

The present study aims to design and synthesize a novel series of chromane-based analogues by structural modifications to improve antibacterial activity [13, 14]. NMR, FT-IR, and mass spectrometry were employed as spectroscopic and analytical methods to characterize and confirm the structures of the produced compounds. The antibacterial efficacy of the compounds was assessed by standard in vitro assays against several bacterial strains, encompassing both Gram-positive bacteria and Gram-negative bacteria, in addition to fungal species [15]. This study's findings aim to aid in the creation of new antimicrobial medicines that can address resistant microbial diseases and offer valuable insights into the structure-activity correlations (SAR) of chromane derivatives [16].

MATERIAL AND METHODS:

MATERIAL:

The chemicals used for this study were purchased from nearby vendors. The compounds infrared spectra were noted. Compounds' ¹H NMR is recorded, and the Agar diffusion method is used to evaluate produced compounds. There are three distinct forms of agar diffusion techniques: the Agar cup method, the Paper disc method, and the Agar ditch method. This experiment employed the Agar cup method. The reference medicine employed was tobramycin.


Step 1: Compound 2: Synthesis of 3-acetyl-6-nitro coumarin

A solution of 3-acetyl coumarin (0.188 g) was formulated in concentrated sulfuric acid (1.10 mL) and subsequently cooled to 0 °C. The amalgamation was agitated for 15 minutes under these parameters. A nitrating mixture, consisting of 0.2 mL of concentrated sulfuric acid and 0.06 mL of nitric acid, was thereafter added gradually while preserving the temperature between 0 and 5 °C. The reaction was permitted to continue with constant stirring for 2 hours at 5 °C. Following completion, the mixture was transferred into 25 mL of crushed ice water. The resultant yellow precipitate was obtained using filtration, rinsed with cold water, and air-dried. The

crude product was purified using silica gel column chromatography employing a 1:1 (v/v) combination of petroleum ether and benzene as the mobile phase, resulting in a 79% yield of 3-acetyl-6-nitro coumarin (Compound 2) [17, 18].

Step 2: Compound 3: Synthesis of 3-acetyl-6-amino coumarin

A refluxing combination of compound 2 (0.233 g), fine iron powder (0.296 g), concentrated hydrochloric acid (1.11 mL), and ethanol (10 mL) was prepared. The effect was sustained under reflux for six hours. Upon cooling to ambient temperature, the resultant solid was subjected to filtration, extensively rinsed with water, and subsequently dried. The crude product underwent recrystallization from ethanol, yielding pure 3-acetyl-6-amino coumarin (Compound 3) with a 72% yield [19, 20].



Scheme 1: Synthesis chromane derivatives

Step 3: Compounds 4a–e: Synthesis of Coumarin–Benzoic Acid Adducts

General Method for the Synthesis of Coumarin–Benzamide Derivatives

Add thionyl chloride (0.141 g) and benzene (1.5 mL) to a stirred mixture of 3-acetyl-6-aminocoumarin

(0.203 g) and substituted benzoic acid. The reaction mixture refluxed for two hours. After completion, the reaction mixture was placed in 25 mL crushed ice water. The precipitate was separated, filtered, dissolved in 1.25 mL 2N NaOH, and filtered again. After acidification with 2N HCl, the crude product was filtered via a Büchner funnel, washed with additional cold water, and concentrated under decreased pressure. The benzamide derivative was obtained by recrystallizing the crude solid from ethanol [21, 22].

Step 4: Compounds 5a–e: Hydrolysis of Coumarin–Benzamide Derivatives

General Procedure for the Synthesis of Coumarin-3-Carboxylic Acids

Each coumarin–benzamide derivative (4a–e) was solubilized in 1.5 mL of water, methanol, and THF. After adding LiOH.H₂O the reaction mixture was stirred at room temperature for 6 hours. After completion, the reaction mixture was acidified with 3M HCl to 2.0 pH and extracted with ethyl acetate. First, the organic layer was dehydrated with anhydrous Na₂SO₄, then filtered and concentrated under reduced pressure. To obtain the carboxylic acid derivative, silica gel column chromatography was used to purify the residue in hexane and ethyl acetate (8:2 v/v) [23, 24].

Evaluation of Antimicrobial Activity of synthesized compounds:

Selection of Bacteria:

The bacteria were chosen for an in vitro investigation.

Gram-positive bacteria	<i>Staphylococcus aureus</i>
	<i>Bacillus subtilis</i>
Gram-negative bacteria	<i>Escherichia coli</i>
	<i>Pseudomonas aeruginosa</i>

Preparing the culture medium:

Agar (2.0 gm), peptone (1.0 gm), sodium chloride (0.5 gm), and meat extracts (0.3 gm) are all utilized in the process of making the culture medium. Together, these components make up the culture medium. Once all of the components, with the exception of agar, had been dissolved in one hundred milliliters of distilled water and the pH of the medium had been adjusted to 7.6, agar was added to it and dispensed in 25-milliliter portions in test tubes that were maintained in separate locations from one another. Following the completion of a twenty-minute sterilization process at a temperature of 121.5 degrees Celsius, the test tubes were then plugged with cotton wool [25-30].

Testing for antibacterial susceptibility involved inoculating nutrient agar broth with 0.5 ml of 24 h old culture medium, stirring the mixture thoroughly, and then putting it onto a sterilized Petri plate (25 ml each). After letting the poured mixture settle for a while, a sterile cup borer was used to pierce the agar surface to create the "cups." A previously sanitized micropipette was used to add the test solution into these "cups." The plates were noticed. All of the synthetic compounds' antibacterial activity was examined in vitro at a concentration of 1000 ppm, and the results are displayed in Tables 1 and 2 as a percentage (%) of inhibition [26, 29-34].

After a period of five days, the percentage of inhibition for bacteria was determined by applying the formula that was provided.

$$\text{Percentage of Inhibition} = 100 [1 - X/Y]$$

Where,

X = Area of colony in control plate.

Y = Area of colony in test plate.

The percentage (%) data are shown in table 1 and 2 as follows;

(+) = Small clearing zone (<50%), slightly active,

(++) = Medium clearing zone (51-55%), moderately active,

(+++)= Large clearing zone (56-60%), highly active and,

(++++)= Very large clearing zone (>60%), very high activity.

RESULT AND DISCUSSION:

Mass spectrometry (MS), ¹H NMR, and infrared spectroscopy were used to confirm the synthesis of coumarin-based derivatives. The suggested structures and the spectral data agreed. All of the produced

compounds' structures are coherently confirmed by the IR, ¹H NMR, and MS data. Successful substitutions at the 6-position and modifications at the 3-position of the coumarin core are supported by distinctive signals for functional groups (acetyl, amide, nitro, amino, halogens, and carboxylic acid). The success of the synthetic process and the impact of substituents on spectral attributes are both demonstrated by the spectral consistency throughout each series.

Evaluation of Antimicrobial Activity of Synthesized compounds:

The compounds tested for antibacterial activity show the percentage (%) of the zone of inhibition of bacterial growth of both Gram-positive and Gram-negative bacteria. The antibacterial qualities of four compounds from Series 1 (4a–e) and four from Series 2 (5a–e) were tested against Gram-positive bacterial strains *B. subtilis* and *S. aureus*, as well as Gram-negative bacterial strains *P. aeruginosa* and *E. Coli*. Compound 4d in Series 1 demonstrated promising activity against the *E. coli* and the *S. aureus* bacterial strains. Compound 5d in Series 2 shown promising efficacy against *B. subtilis* and *P. aeruginosa* bacterial strains.

Table 1: % Zone of Inhibition synthesized Compounds 4a-e

Compounds	Zone of Inhibition			
	Gram Positive Bacteria		Gram Negative Bacteria	
	<i>Staphylococcus Aureus</i>	<i>Bacillus Subtilis</i>	<i>E Coli</i>	<i>Pseudomonas aeruginosa</i>
4a	++	+	++	+
4b	+	++	++	++
4c	+	+++	++	+++
4d	+++	++	+++	++
4e	++	++	++	++
Tobramycin	+++	++++	++++	++++

Table 2: % Zone of Inhibition synthesized Compounds 5a-e

Compounds	Zone of Inhibition			
	Gram Positive		Gram Negative	
	<i>Staphylococcus Aureus</i>	<i>Bacillus subtilis</i>	<i>E Coli</i>	<i>Pseudomonas aeruginosa</i>
5a	++	++	++	++
5b	+	+	++	++
5c	++++	++	++++	+++
5d	+++	++++	+++	++++
5e	+++	++	++	++
Tobramycin	+++	++++	++++	++++

CONCLUSION:

All of the structures of the compounds that were synthesized have been confirmed in a consistent manner by the IR, ¹H NMR, and MS investigations. Distinct signals for functional groups (acetyl, amide, nitro, amino, halogens, and carboxylic acid) provide support for successful substitutions at the 6-position and modifications at the 3-position of the coumarin core. These signals are necessary for the successful substitutions and modifications. The spectral consistency that is present throughout each series is evidence of both the efficacy of the synthetic process and the influence that substituents have on the spectral characteristics of the compounds. N-(3-acetyl-coumarin-6-yl) is a formula. Despite the fact that -4-nitrobenzamide, which is the molecule 6-(4-nitrobenzamido)-2-oxo-2H-chromene-3-carboxylic acid, demonstrates the strongest antibacterial activity, additional research is necessary to discover the chemical mechanism.

DECLARATIONS:

Consent for publication:

All the authors approved the manuscript for publication.

Competing interests:

All authors declare no competing interests.

Funding:

Not applicable.

REFERENCES

1. Alzahrani, A.Y., 2023. Design, synthesis, characterization, and antimicrobial evaluation of some new pyridine and chromene derivatives containing Lidocaine analogue. *Journal of Saudi Chemical Society*, 27(2), p.101620.
2. Shaban, S.S., Haneen, D.S., Abou-El-Regal, M.M. and El-Metwally, S.A., 2024. Design, synthesis and antibacterial assessment of novel 4 H-chromene analogues. *Synthetic Communications*, 54(7), pp.600-611.
3. Karnik, K.S., Sarkate, A.P., Tiwari, S.V., Azad, R. and Wakte, P.S., 2022. Design, synthesis, biological evaluation and in silico studies of EGFR inhibitors based on 4-oxo-chromane scaffold targeting resistance in non-small cell lung cancer (NSCLC). *Medicinal Chemistry Research*, 31(9), pp.1500-1516.
4. H. Afifi, T., M. Okasha, R., Alsharif, H., EA Ahmed, H. and S. Abd-El-Aziz, A., 2017. Design, synthesis, and docking studies of 4H-chromene and chromene based azo chromophores: a novel series of potent antimicrobial and anticancer agents. *Current Organic Synthesis*, 14(7), pp.1036-1051.
5. Kamboj, S., Chaudhary, J., Jain, A. and Singh, R., 2023. In vitro and in vivo Antidiabetic Evaluation of Synthesised Novel New Chromane and its Derivatives. *Journal of Young Pharmacists*, 15(2), pp.292-297.
6. Mpitimpiti, A.N., Petzer, J.P., Petzer, A., Jordaan, J.H. and Lourens, A.C., 2019. Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase. *Molecular Diversity*, 23(4), pp.897-913.
7. Arumugam, N., Alkaltham, M.F., Viswanathan, V., Almansour, A.I., Kumar, R.S., Alaqeel, S.I., Kumar, S.Y., Padmanaban, R., Mahalingam, S.M. and Dege, N., 2023. Design, synthesis, structural characterization and computational studies of new class of spirooxindolopyrrolidine embedded chromanone hybrid heterocycles. *Journal of Molecular Structure*, 1286, p.135539.
8. Alshaye, N.A. and Ibrahim, M.A., 2023. Design, synthesis, characterization, and antimicrobial evaluation of the novel 2-heteroarylchromeno [2, 3-d] pyrimidines. *Synthetic Communications*, 53(10), pp.744-754.
9. Rawat, P. and Verma, S.M., 2016. Design and synthesis of chroman derivatives with dual anti-breast cancer and antiepileptic activities. *Drug Design, Development and Therapy*, pp.2779-2788.
10. Tiwari, S.V., Seijas, J.A., Vazquez-Tato, M.P., Sarkate, A.P., Karnik, K.S. and Nikalje, A.P.G., 2018. Ionic liquid-promoted synthesis of novel chromone-pyrimidine coupled derivatives, antimicrobial analysis, enzyme assay, docking study and toxicity study. *Molecules*, 23(2), p.440.
11. Ayati, A., Falahati, M., Irannejad, H. and Emami, S., 2012. Synthesis, in vitro antifungal evaluation and in silico study of 3-azoyl-4-chromanone phenylhydrazones. *DARU Journal of Pharmaceutical Sciences*, 20(1), p.46.
12. Pini, E., Poli, G., Tuccinardi, T., Chiarelli, L.R., Mori, M., Gelain, A., Costantino, L., Villa, S., Meneghetti, F. and Barlocco, D., 2018. New chromane-based derivatives as inhibitors of *Mycobacterium tuberculosis* salicylate synthase (MbtI): preliminary biological evaluation and molecular modeling studies. *Molecules*, 23(7), p.1506.
13. Arumugam, N., Soliman, S.M., Viswanathan, V., Almansour, A.I., Kumar, R.S., Mahalingam, S.M., Krishnamoorthy, B.S., Dege, N., Karuppiyah, P. and Perumal, K., 2023. Environmentally-friendly synthesis, structural determination and antimicrobial activity of new class of spiropyrrolidine embedded with indenoquinoline and chromanone heterocyclic units. *Journal of Molecular Structure*, 1293, p.136189.
14. Feliciano, A., Gómez-García, O., Escalante, C.H., Rodríguez-Hernández, M.A., Vargas-Fuentes, M., Andrade-Pavón, D., Villa-Tanaca, L., Álvarez-Toledano, C., Ramírez-Apan, M.T., Vázquez, M.A. and Tamariz, J., 2021. Three-Component Synthesis of 2-Amino-3-cyano-4 H-chromenes, In Silico Analysis of Their Pharmacological Profile, and In Vitro Anticancer and Antifungal Testing. *Pharmaceuticals*, 14(11), p.1110.
15. Feng, L., Maddox, M.M., Alam, M.Z., Tsutsumi, L.S., Narula, G., Bruhn, D.F., Wu, X., Sandhaus, S., Lee, R.B., Simmons, C.J. and Tse-Dinh, Y.C., 2014. Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olmpicin A and derivatives. *Journal of medicinal chemistry*, 57(20), pp.8398-8420.
16. Mohsin, N.U.A., Irfan, M., Hassan, S.U. and Saleem, U., 2020. Current strategies in development of new chromone derivatives with diversified pharmacological activities: A review. *Pharmaceutical chemistry journal*, 54(3), pp.241-257.
17. Yurttas, L., Temel, H.E., Aksoy, M.O., Bülbül, E.F. and Çiftçi, G.A., 2022. New chromanone derivatives containing thiazoles: Synthesis and antitumor activity evaluation on A549 lung cancer cell line. *Drug Development Research*, 83(2), pp.470-484.
18. Kamdar, N.R., Haveliwala, D.D., Mistry, P.T. and Patel, S.K., 2011. Synthesis and evaluation of in vitro antitubercular activity and antimicrobial activity of some novel 4 H-chromeno [2, 3-d] pyrimidine via 2-amino-4-phenyl-4 H-chromene-3-carbonitriles. *Medicinal Chemistry Research*, 20(7), pp.854-864.
19. Ramadan, K.M., El-Beltagi, H.S., Iqbal, Z. and Bendary, E.S., 2022. The synthesis, fungicidal activity, and in silico study of alkoxy analogues of natural precocenes I, II, and III. *Molecules*, 27(21), p.7177.
20. Yousif, M.N., Fathy, U. and Yousif, N.M., 2023. Synthesis and anticancer activity of novel chromene derivatives,

chromeno [2, 3-d][1, 3] oxazines, and chromeno [2, 3-d] pyrimidines. *Medicinal Chemistry*, 19(6), pp.578-585.

21. Jadhav, S.R., Karan Kumar, B., Joshi, R.P., Suryakant, C.K., Chandu, A., Muzaffar-Ur-Rehman, M., Khetmalis, Y.M., Nandikolla, A., Murugesan, S. and Chandra Sekhar, K.V., 2023. Retrospective review of chromane analogues as anti-protozoal leads: a decade's worth of evolution. *Current Topics in Medicinal Chemistry*, 23(9), pp.713-735.
22. Assirey, E., Alsaggaf, A., Naqvi, A., Moussa, Z., Okasha, R.M., Afifi, T.H. and Abd-El-Aziz, A.S., 2020. Synthesis, biological assessment, and structure activity relationship studies of new flavanones embodying chromene moieties. *Molecules*, 25(3), p.544.
23. Chouchène, N., Toumi, A., Boudriga, S., Edziri, H., Sobeh, M., Abdelfattah, M.A., Askri, M., Knorr, M., Strohmman, C., Brieger, L. and Soldara, A., 2022. Antimicrobial activity and DFT studies of a novel set of spiropyrrolidines tethered with thiochroman-4-one/chroman-4-one scaffolds. *Molecules*, 27(3), p.582.
24. Li, X., Li, T., Zhan, F., Cheng, F., Lu, L., Zhang, B., Li, J., Hu, Z., Zhou, S., Jia, Y. and Allen, S., 2022. Design, synthesis, and biological evaluation of novel chromanone derivatives as multifunctional agents for the treatment of Alzheimer's disease. *ACS Chemical Neuroscience*, 13(23), pp.3488-3501.
25. Mokale, S.N., Begum, A., Sakle, N.S., Shelke, V.R. and Bhavale, S.A., 2017. Design, synthesis and anticancer screening of 3-(3-(substituted phenyl) acryloyl)-2H-chromen-2-ones as selective anti-breast cancer agent. *Biomedicine & Pharmacotherapy*, 89, pp.966-972.
26. Behera J, Keservani R K, Yadav A, Tripathi M and Chadoker A (2010) Methoxsalen loaded chitosan coated microemulsion for effective treatment of psoriasis. *Int. J. Drug Del.* 2, 159-167.doi:10.5138/ijdd.2010.0975.0215.02025
27. Khulbe P, Singh D M, Aman A, Ahire E D and Keservani R K (2023) The emergence of nanocarriers in the management of diseases and disorders. *Community Acquired Infection* 2023, 10. <https://doi.org/10.54844/cai.2022.0139>
28. Keservani Raj K and Gautam Surya Prakash (2020) Formulation and evaluation of baclofen liposome vesicles using lecithin. *ARS Pharmaceutica* 61 (3), 175-180. <http://dx.doi.org/10.30827/ars.v61i3.15279>
29. Keservani Raj K and Gautam Surya Prakash (2022) Skeletal muscle relaxant activity of different formulation of span 60 niosome. *ARS Pharmaceutica* 63 (1), 32-44. <https://dx.doi.org/10.30827/ars.v63i1.22264>
30. Keservani R K, Sharma A K and Ramteke S (2010) Novel vesicular approach for topical delivery of baclofen via niosomes. *Lat. Am J. Pharm.* 29, 1364-1370.
31. Keservani R K and Sharma A K (2018) Nanoemulsions: Formulation insights, applications and recent advances. *Nanodispersions for Drug Delivery* 2018, 71-96. eBook ISBN-9781351047562
32. Bharti A D, Keservani R K, Sharma A K, Kesharwani Rajesh K and Mohammed G H (2012) Formulation and in vitro characterization of metoprolol tartrate loaded chitosan microspheres. *Ars Pharmaceutica* 53-3, 13-18.
33. Benny, A.T., Arikatt, S.D., Vazhappilly, C.G., Kannadasan, S., Thomas, R., Leelabaiamma, M.S., Radhakrishnan, E.K. and Shanmugam, P., 2022. Chromone, a privileged scaffold in drug discovery: Developments in the synthesis and bioactivity. *Mini Reviews in Medicinal Chemistry*, 22(7), pp.1030-1063.
34. Ghatpande, N.G., Jadhav, J.S., Kaproormath, R.V., Soliman, M.E. and Shaikh, M.M., 2020. A brief overview on recent advances in spiro [chromane-2, 4'-piperidine]-4 (3H)-one-functionalized compounds in medicinal chemistry research. *Bioorganic & Medicinal Chemistry*, 28(23), p.115813.